• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

生产与市场：合理解决卡介苗短缺问题。

Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin.

机构信息

Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

出版信息

Eur Urol Focus. 2018 Jul;4(4):481-484. doi: 10.1016/j.euf.2018.06.018. Epub 2018 Jul 11.

DOI:10.1016/j.euf.2018.06.018
PMID:30005997
Abstract

Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.

摘要

卡介苗（BCG）用于非肌肉浸润性膀胱癌肿瘤切除后的一线膀胱内治疗。BCG 的主要生产商在过去十年内宣布短缺，导致全球范围内短缺。我们回顾了研究 BCG 短缺的文献，并提出了解决这一问题的方法。

相似文献

1
Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin.生产与市场：合理解决卡介苗短缺问题。
Eur Urol Focus. 2018 Jul;4(4):481-484. doi: 10.1016/j.euf.2018.06.018. Epub 2018 Jul 11.
2
Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.卡介苗短缺与膀胱癌复发的相关性：一项单中心回顾性研究。
Urol Oncol. 2020 Nov;38(11):851.e11-851.e17. doi: 10.1016/j.urolonc.2020.07.014. Epub 2020 Aug 13.
3
Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guérin Connaught Strain for Bladder Cancer Patients.膀胱癌患者卡介苗康诺特株短缺的复发率和成本后果。
Eur Urol Focus. 2021 Jan;7(1):111-116. doi: 10.1016/j.euf.2019.04.002. Epub 2019 Apr 18.
4
Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages.卡介苗供应短缺时代卡介苗在非肌层浸润性膀胱癌中的应用
Urology. 2019 Feb;124:120-126. doi: 10.1016/j.urology.2018.07.055. Epub 2018 Sep 13.
5
Bacillus Calmette-Guérin Manufacturing and SWOG S1602 Intergroup Clinical Trial.卡介苗制造与SWOG S1602组间临床试验
J Urol. 2017 Mar;197(3 Pt 1):538-540. doi: 10.1016/j.juro.2016.12.024. Epub 2016 Dec 16.
6
Critical shortage in BCG immunotherapy: How did we get here and where will it take us?卡介苗免疫治疗的严重短缺：我们是如何走到这一步的，它将把我们带向何方？
Urol Oncol. 2022 Jan;40(1):1-3. doi: 10.1016/j.urolonc.2021.09.022. Epub 2021 Nov 5.
7
Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.卡介苗维持治疗在中高危非肌层浸润性膀胱癌经尿道膀胱肿瘤完全切除术后的作用不显著：一项随机试验的结果
Int J Urol. 2016 Oct;23(10):854-860. doi: 10.1111/iju.13167. Epub 2016 Jul 15.
8
Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.立足坚实基础：增强卡介苗疗法。
Eur Urol Focus. 2018 Jul;4(4):485-493. doi: 10.1016/j.euf.2018.10.010. Epub 2018 Nov 8.
9
Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.卡介苗膀胱内灌注治疗非肌层浸润性膀胱癌：综述
Int J Urol. 2018 Jan;25(1):18-24. doi: 10.1111/iju.13410. Epub 2017 Jul 25.
10
Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer.膀胱癌非肌层浸润性：膀胱内联合化疗
Eur Urol Focus. 2018 Jul;4(4):503-505. doi: 10.1016/j.euf.2018.07.005. Epub 2018 Jul 14.

引用本文的文献

1
Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study.吡柔比星与卡介苗膀胱内热化疗治疗高危非肌层浸润性膀胱癌患者的比较：一项回顾性研究
BMC Urol. 2025 Apr 9;25(1):81. doi: 10.1186/s12894-025-01773-z.
2
Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Response to Bacillus Calmette-Guérin Immunotherapy in Bladder Cancer Patients.谷胱甘肽-S-转移酶 theta 2（GSTT2）调节膀胱癌患者对卡介苗免疫治疗的反应。
Int J Mol Sci. 2024 Aug 16;25(16):8947. doi: 10.3390/ijms25168947.
3
Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection.
研究卡介苗接种预防新型冠状病毒肺炎感染潜力的随机临床试验原理
Bladder Cancer. 2021 May 25;7(2):121-131. doi: 10.3233/BLC-201529. eCollection 2021.
4
Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.用于 BCG 无应答的高危非肌肉浸润性膀胱癌的新型免疫治疗选择。
Cancer Med. 2023 Dec;12(24):21944-21968. doi: 10.1002/cam4.6768. Epub 2023 Dec 1.
5
Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer.低剂量诱导卡介苗治疗非肌层浸润性膀胱癌的短期疗效降低
Cancers (Basel). 2023 Jul 24;15(14):3746. doi: 10.3390/cancers15143746.
6
Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis.膀胱内热化疗作为卡介苗灌注治疗非肌层浸润性膀胱癌的一种有前景的替代方法：一项网状荟萃分析。
Front Oncol. 2023 May 12;13:1164932. doi: 10.3389/fonc.2023.1164932. eCollection 2023.
7
Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.丝裂霉素C膀胱内热化疗治疗高危非肌层浸润性膀胱癌患者
BJUI Compass. 2022 Dec 2;4(3):314-321. doi: 10.1002/bco2.203. eCollection 2023 May.
8
Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage.卡介苗药物短缺期间全州非肌肉浸润性膀胱癌膀胱内治疗率的变化。
Urology. 2023 Jul;177:74-80. doi: 10.1016/j.urology.2023.02.044. Epub 2023 Mar 25.
9
How to Perform Intravesical Chemotherapy after Second TURBT for Non-Muscle-Invasive Bladder Cancer: A Single-Center Experience.非肌层浸润性膀胱癌二次经尿道膀胱肿瘤电切术后膀胱内化疗的实施方法：单中心经验
J Clin Med. 2022 Dec 26;12(1):169. doi: 10.3390/jcm12010169.
10
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.循环式高热膀胱内化疗联合丝裂霉素 C（HIVEC）与卡介苗用于高危非肌肉浸润性膀胱癌：HIVEC-HR 随机临床试验结果。
World J Urol. 2022 Apr;40(4):999-1004. doi: 10.1007/s00345-022-03928-1. Epub 2022 Jan 17.